top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for introduction of radioactive material and continued positive momentum toward initiating Alpha DaRT treatment manufacturing in 2026 - Jerusalem, October 21, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the deve
7 days ago
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
- First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – - Study...
Sep 2
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, August 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 27
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical PromiseAn interview with Prof. Aron Popovtzer
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical Promise An interview with Prof. Aron Popovtzer, Director of Sharett...
Jul 10
Alpha Tau to Present at Jefferies Global Healthcare Conference
JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 28
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...
May 20
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
May 13
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 6, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 6
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S....
Apr 28
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy...
Apr 2
bottom of page